Agios Pharmaceuticals (AGIO) Other Non Operating Income (2021 - 2026)

Agios Pharmaceuticals (AGIO) has 6 years of Other Non Operating Income data on file, last reported at $119000.0 in Q2 2026.

• Quarterly Other Non Operating Income fell 77.25% year-over-year to $119000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $418000.0 (down 91.72% YoY) and the FY2025 annual result came in at $2.0 million, down 69.85% from the prior year.
• Other Non Operating Income was little changed at $119000.0 in Q2 2026, from $119000.0 in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $3.0 million in Q1 2022 to a low of $67000.0 in Q3 2025.
• A 5-year average of $1.2 million and a median of $1.3 million in 2022 frame the typical range for Other Non Operating Income.
• Annual changes were most pronounced in 2024 — Other Non Operating Income surged 37.81% — and 2025, when it tumbled 95.94%.
• Tracing AGIO's Other Non Operating Income over 5 years: stood at $1.4 million in 2022, then advanced by 26.23% to $1.7 million in 2023, then retreated by 5.25% to $1.6 million in 2024, then slumped by 93.04% to $113000.0 in 2025, then rose by 5.31% to $119000.0 in 2026.
• The last three Other Non Operating Income figures came in at $119000.0 (Q2 2026), $119000.0 (Q1 2026), and $113000.0 (Q4 2025), per Business Quant data.